HeartWare Selects Allen & Caron for Investor Relations and...

HeartWare Selects Allen & Caron for Investor Relations and Corporate Communications

FRAMINGHAM, Mass., March 24 /PRNewswire/ -- HeartWare Inc. (ASX: HTW),
a developer and manufacturer of miniaturized implantable heart pumps to
treat advanced heart failure, today announced it has selected Allen & Caron
Inc as its agency for investor relations and corporate communications.
Allen & Caron Inc has offices in New York, Irvine, CA, and London.

HeartWare Chief Executive Douglas Godshall said: "There is a very
significant opportunity for our miniaturized heart pump, which was designed
to be the least invasive full output pump on the global market. In the U.S.
alone more than 5 million patients suffer from heart failure and fewer than
3,000 donor hearts become available each year. With an international
clinical trial underway that is showing very promising results and plans to
commence a clinical trial in the U.S. in the first half of this year, we
believe it is the appropriate time to strengthen our proactive investor
relations program in order to more effectively deliver our message to the
investment community in Australia, the U.S. and across Europe. We selected
Allen & Caron because of its reputation and track record of successfully
introducing companies to a new and broader audience of analysts,
institutional investors and other investment community professionals."

Allen & Caron Partner Matt Clawson said: "HeartWare is an important new
client that is bringing a much-needed advancement to the cardiovascular
marketplace and we are pleased to be joining forces with management to get
the word out. The company has a sound business plan and has the potential
to help thousands of terminally ill patients all over the world. We are
assisting HeartWare in developing and executing an investor relations
program designed to communicate its business plan, improve awareness among
portfolio managers and analysts and over time, enhance shareholder value as
the company progresses through its upcoming milestones."

About HeartWare

HeartWare (ASX: HTW) develops and manufactures miniaturized implantable
heart pumps, or Left Ventricular Assist Devices ("LVADs"), to treat
patients suffering from advanced heart failure. The Company is developing
the industry's smallest and least invasive pumps, which it believes will be
the key to unlocking the potential of a large and underserved market. The
HeartWare(R) LVAD is the only full-output pump designed to be implanted in
the chest, avoiding the abdominal surgery generally required to implant
competing devices. The device is currently the subject of an international
clinical trial involving five investigational centers in Europe and
Australia. A clinical trial in the U.S. is expected to begin in the first
half of 2008.

About Allen & Caron

Allen & Caron is a full-service corporate, investor and marketing
communications agency serving the needs of public companies. The Allen &
Caron international client base includes emerging growth companies in a
range of industry segments. The firm has offices in Irvine, California; New
York City and London; maintains representation in Paris; and has an
affiliate relationship with a leading investor relations firm in Italy,
with offices in Milan and Rome.